Skip to main content
DSKYF logo

Daiichi Sankyo Company, Limited (DSKYF) Stock Price & Analysis

Daiichi Sankyo Company, Limited (DSKYF) — price $17.72 (0.00%), as of the Nov 19, 2026 trading session; market cap $32.3B.

Educational signal · not a buy or sell recommendation · How to read this

$17.72 $0.00 (0.00%) Market Cap $32.3B

Daiichi Sankyo Company, Limited · DSKYF · Healthcare · Drug Manufacturers - General

Daiichi Sankyo Company, Limited operates as a global pharmaceutical powerhouse, dedicated to the research, development, manufacturing, and worldwide commercialization of a wide array of medicinal products.

Price as of Nov 19, 2026

Key Statistics

No MoonshotScore yet: we have not published a score for this company.

Thousands of the 20,000+ US stocks here carry a MoonshotScore.

Scored companies in the same industry:

  • BIIB · Biogen Inc. · 37 /100
  • GSK · GSK plc · 77 /100
  • SNY · Sanofi · 87 /100

See all scored stocks →

Price & valuation

Dates shown where recorded
MeasureValueAs of
Latest provided price$17.72
Change on the day0.00%
52-week range$13.85–$25.75
Market capitalisation$32.3B—
Price / earnings (trailing)18.00
Shares traded on the day773
Beta (volatility vs the S&P 500)0.12

Price & events

Weekly closing price with reported quarters marked Weekly closing price from Oct 17, 2025 to Nov 19, 2026: low $15, high $26, latest $18. $26 $15 high $26 Oct 17, 2025 Nov 19, 2026 · $18 $25Oct 17, 2025$23Oct 31, 2025$22Nov 14, 2025$24Nov 28, 2025$21Dec 12, 2025$22Dec 26, 2025$24Jan 9, 2026$20Jan 23, 2026$18Feb 6, 2026$19Feb 20, 2026$18Mar 6, 2026$19Mar 20, 2026$18Apr 2, 2026$19Apr 17, 2026$16May 1, 2026$17May 15, 2026$17May 29, 2026$16Jun 12, 2026$16Jun 26, 2026$18Jul 10, 2026$16Jul 24, 2026$17Aug 7, 2026$18Aug 21, 2026$18Sep 4, 2026$19Sep 18, 2026$18Oct 2, 2026$17Oct 16, 2026$17Oct 30, 2026$18Nov 13, 2026

Point at or tab to any week for its close.

Other perspectives

Council score for Daiichi Sankyo Company (DSKYF): perspectives

Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.

Legends Council

5 lenses, 0 current

AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built

Dalio-style lens (simulated) Ray Dalio Favorable read
Simons-style lens (simulated) Jim Simons Neutral read
Englander-style lens (simulated) Izzy Englander Favorable read
Klarman-style lens (simulated) Seth Klarman Favorable read
Moon AI lens (model) Favorable read

Read on: Sep 10, 2026 · older than the 27 hours refresh window; not a current reading

Munger's Mindset

Balance Sheet & Valuation · historical

Financial Health Moderate
Margin of Safety Fairly Valued
Profit Margin Neutral
Revenue Growth Moderate
Debt/Equity Moderate
ROE Moderate
Gross Margin Strong

Read on: Sep 10, 2026 · older than the 27 hours refresh window; not a current reading

How to read these bars and different assessments

Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.

Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.

On Sep 10, 2026, the Munger lens read the price at that time as fairly valued against its own estimate of value.

Readings on this page are from Nov 20, 2026, except a card that shows its own read date.

1 · What is it?

What is Daiichi Sankyo Company (DSKYF), and what does it report?

Short answer · as of

Daiichi Sankyo researches, manufactures and commercializes prescription medicines worldwide from its Tokyo base.

Research dated 2026-09-12.

Its products span oncology, cardiovascular and neurological care, pain, diabetes, bone health, infections and other conditions, complemented by vaccines, consumer brands, active ingredients and chemical intermediates.

The reported results therefore measure a diversified pharmaceutical group rather than a pure oncology developer. Enhertu is the distinctive growth platform, but consolidated revenue also includes mature medicines and brands such as Lulu, Loxonin S, Transino and Minon; the income statement does not isolate those economics in the figures shown here.

2 · Latest results

What do the latest results show for Daiichi Sankyo Company (DSKYF)?

Short answer · as of

The most recent reported quarter, Q2 FY2027, carried revenue of ¥599.02B. Against analyst estimates the company has EPS beat 5 of the last 8 reports.

Quarterly income statement — 4 quarters
Revenue, net income and earnings per share by quarter
PeriodRevenueNet incomeEPS
Q2 FY2027¥599.02B¥85.35B¥46.15 (diluted)
Q1 FY2027¥570.58B¥68.14B¥37.13 (diluted)
Q4 FY2026¥593.30B¥42.70B¥23.97 (diluted)
Q3 FY2026¥558.59B¥86.71B¥46.80 (diluted)
3 · Financial strengths and risks

What are the financial strengths and risks for Daiichi Sankyo Company (DSKYF)?

Short answer · as of

The distress and quality screens read Altman Z 2.93 · Piotroski F 6. Trailing ratios: ROE 17.6% · ROA 4.6% · current ratio 2.81.

The records behind this page

Who holds the shares?

Institutional ownership reported through 13F filings.

Tracked investors

Which of the 16 named investors we follow held DSKYF in their latest 13F filing, and what they did against the filing before it.

None of the 16 tracked investors reported DSKYF in their latest 13F filing.

See all tracked investor portfolios

How to read these figures

These filings arrive after the quarter ends. Names appear as the provider lists them, not as a verified ranking, and without filing dates. Related managers can appear separately, so their shares are not added together. Tracked investors: each fund's own latest 13F, so funds that have not filed the newest quarter yet show their previous one; weight is the share of the fund's reported 13F value.

What has been published about Daiichi Sankyo Company (DSKYF)?

Read these with our analysis →

Daiichi Sankyo Company Healthcare Stock: Key Questions Answered

The last question is answered from this page's own dated data, not from the research.

What makes Enhertu important to Daiichi Sankyo?

Enhertu places an antibody-drug conjugate at the center of Daiichi Sankyo’s oncology offering. Its commercial contribution sits within a much broader portfolio of prescription medicines, vaccines and consumer products.

Why is Daiichi Sankyo developing Guardant’s companion diagnostic?

The collaboration is intended to identify patients with advanced metastatic non-small cell lung cancer for treatment with Enhertu. That links diagnostic selection directly to the addressable use of the therapy.

How do Lulu and Loxonin S change Daiichi Sankyo’s business mix?

Lulu and Loxonin S give Daiichi Sankyo consumer health exposure alongside prescription medicines. Transino, Minon and oral-care brands broaden that presence further, making the group more diversified than an oncology-only developer.

What is the DSKYF stock price today?

The last price recorded for Daiichi Sankyo Company, Limited (DSKYF), with its trading session and source, is listed under Price & valuation on this page. It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.

Research written by Codex (gpt-5.6-sol) on 2026-09-12. AI-authored analysis; source dates are listed under Sources. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.

Sources: the source register lists the 17 figures on this page — 14 from Financial Modeling Prep (FMP) and 3 with no recorded source. Its rows (value as shown, as-of date, tier and source link) are in the Markdown version of this page.

Publication details and research sources
Published
Research standards
Methodology · Editorial policy · Corrections

Sources (as of 2026-09-12), by section of the research

  • 1. What is Daiichi Sankyo Company (DSKYF), and what does it report?: Legal name; Ticker / exchange; Headquarters; Sector / industry (provider taxonomy); Business description; Named officers
  • FAQ: What makes Enhertu important to Daiichi Sankyo?: Business description
  • FAQ: Why is Daiichi Sankyo developing Guardant’s companion diagnostic?: Business description
  • FAQ: How do Lulu and Loxonin S change Daiichi Sankyo’s business mix?: Business description
Data Sources & Methodology
Figures come from Financial Modeling Prep (FMP). If FMP has no figure for a ticker, a price or fundamental may come from a Yahoo Finance fallback, or a price from an Alpaca fallback. SEC EDGAR is used only for filing links and company identity details (legal name, address), never for figures. AI analysis by Stock Expert AI proprietary algorithms. Technical indicators via industry-standard calculations. Last updated: .
Data Provenance
Sources: Financial Modeling Prep (FMP) — Primary · Yahoo Finance — Fallback · Alpaca — Tertiary
Last fetched:
Cache TTL: Quote 5min · Profile 7d · Financials 7d · Insider 48h
How we use AI: Numbers are pulled directly from FMP & Yahoo Finance — our AI writes the analysis, it never edits the figures.